Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

128.44 

0.76 0.6%

as of Apr 18 '19

52 Week Range:

113.52 184.00


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also develops Solriamfetol for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea, as well as in Phase II clinical trial for EDS associated with Parkinson's disease; Vyxeos for acute myeloid leukemia; and JZP-258 to treat EDS and cataplexy with narcolepsy and potential treatment of idiopathic hypersomnia and a chronic neurological disorder. In addition, it sells psychiatry and other products. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; and XL-protein GmbH. The company is headquartered in Dublin, Ireland.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) -3.23
-2.33
0.76
3.33
19.32
21.50
22.11
25.50
28.69
40.95
52.65
growth rate 0.0% 100.0% 338.2% 480.2% 11.3% 2.8% 15.3% 12.5% 42.7% 28.6%
Earnings BIT -184.34
-6.84
32.78
124.98
177.36
372.00
450.02
557.92
640.10
613.84
715.93
growth rate 0.0% 100.0% 281.3% 41.9% 109.7% 21.0% 24.0% 14.7% -4.1% 16.6%
Avg.PE -1.00
-18.40
23.64
14.47
12.27
36.10
182.89
24.89
23.44
24.37
14.88
growth rate 0.0% 100.0% -38.8% -15.2% 194.2% 406.6% -86.4% -5.8% 4.0% -38.9%
ROA -113.42
-6.08
26.96
64.21
26.00
10.29
2.09
9.84
9.73
9.83
8.66
growth rate 0.0% 100.0% 138.2% -59.5% -60.4% -79.7% 370.8% -1.1% 1.0% -11.9%
ROE 229.30
9.40
107.30
111.92
43.92
17.90
4.38
22.19
22.83
21.26
16.35
growth rate -95.9% 1,041.5% 4.3% -60.8% -59.2% -75.5% 406.6% 2.9% -6.9% -23.1%
ROIC 113.36
25.91
12.64
2.56
11.95
11.83
11.90
10.34
growth rate -77.1% -51.2% -79.8% 366.8% -1.0% 0.6% -13.1%
Cur. Ratio 0.25
0.62
1.24
3.77
2.88
4.24
4.69
5.55
2.91
3.29
3.57
growth rate 148.0% 100.0% 204.0% -23.6% 47.2% 10.6% 18.3% -47.6% 13.1% 8.5%
Quick Ratio 0.19
0.47
1.12
3.64
2.42
3.73
4.01
5.29
2.56
2.81
3.15
growth rate 147.4% 138.3% 225.0% -33.5% 54.1% 7.5% 31.9% -51.6% 9.8% 12.1%
Leverage 4.44
1.32
1.75
1.73
2.44
2.10
2.56
1.89
1.89
growth rate -70.3% 32.6% -1.1% 41.0% -13.9% 21.9% -26.2% 0.0%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 6.60
12.30
22.10
34.37
75.00
125.00
186.37
209.69
234.24
224.13
263.84
growth rate 86.4% 79.7% 55.5% 118.2% 66.7% 49.1% 12.5% 11.7% -4.3% 17.7%
Acct.Payable 39.91
16.00
21.00
25.13
21.81
22.42
24.37
40.60
growth rate -59.9% 31.3% 19.7% -13.2% 2.8% 8.7% 66.6%
Cur.Assets 44.00
37.00
74.50
199.13
552.00
865.00
1,015.85
1,257.67
748.07
968.28
1,234.01
growth rate -15.9% 101.4% 167.3% 177.2% 56.7% 17.4% 23.8% -40.5% 29.4% 27.4%
Total Assets 117.50
107.40
135.70
253.57
1,966.00
2,238.00
3,338.96
3,332.61
4,800.23
5,123.67
5,203.49
growth rate -8.6% 26.4% 86.9% 675.3% 13.8% 49.2% -0.2% 44.0% 6.7% 1.6%
Cash 24.90
15.60
44.80
82.08
387.00
637.00
684.04
988.79
365.96
386.04
309.62
growth rate -37.4% 187.2% 83.2% 371.5% 64.6% 7.4% 44.6% -63.0% 5.5% -19.8%
Inventory 4.30
3.40
5.00
3.91
27.00
29.00
30.04
19.45
34.05
43.25
52.96
growth rate -20.9% 47.1% -21.8% 590.7% 7.4% 3.6% -35.2% 75.1% 27.0% 22.5%
Cur.Liabilities 173.50
59.20
59.90
52.87
192.00
204.00
216.80
226.64
257.41
293.95
345.49
growth rate -65.9% 1.2% -11.7% 263.2% 6.3% 6.3% 4.5% 13.6% 14.2% 17.5%
Liabilities 210.40
180.20
105.20
60.79
845.00
943.00
1,967.75
1,733.97
2,922.89
2,410.58
2,446.07
growth rate -14.4% -41.6% -42.2% 1,290.2% 11.6% 108.7% -11.9% 68.6% -17.5% 1.5%
LT Debt 0.00
91.10
24.60
0.00
427.00
544.00
1,333.00
1,150.86
1,993.53
1,540.43
1,563.03
growth rate -73.0% -100.0% 27.4% 145.0% -13.7% 73.2% -22.7% 1.5%
Equity -80.39
-72.83
30.60
192.79
1,121.29
1,295.53
1,371.14
1,598.65
1,877.34
2,713.10
2,757.42
growth rate 0.0% 100.0% 530.0% 481.6% 15.5% 5.8% 16.6% 17.4% 44.5% 1.6%
Common Shares 26.00
30.00
39.00
47.00
60.00
62.00
63.00
63.00
62.00
61.00
61.00
growth rate 15.4% 30.0% 20.5% 27.7% 3.3% 1.6% 0.0% -1.6% -1.6% 0.0%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 1.70
0.10
0.70
1.28
6.00
10.00
36.35
35.96
9.69
28.95
20.37
growth rate -94.1% 600.0% 82.7% 369.1% 66.7% 263.5% -1.1% -73.1% 198.9% -29.6%
Cash Dividends 0.00 0.00 0.00 0.00 0.00
growth rate
Cash From OA -130.23
-15.88
58.90
151.60
250.00
288.00
407.61
531.94
592.39
693.09
798.90
growth rate 0.0% 100.0% 157.4% 64.9% 15.2% 41.5% 30.5% 11.4% 17.0% 15.3%
FCF per Share -6.20
-0.73
1.37
2.75
3.78
4.78
2.08
7.62
5.56
9.32
10.35
growth rate 0.0% 100.0% 100.7% 37.5% 26.5% -56.5% 266.4% -27.0% 67.6% 11.1%
Sale Purchase of Stock 16.42
25.00
-105.78
58.49
40.52
24.17
31.82
growth rate 52.3% -100.0% 100.0% -30.7% -40.3% 31.7%
FCF -159.00
-22.00
54.00
146.00
227.00
272.00
167.00
496.00
409.00
579.00
667.00
growth rate 0.0% 100.0% 170.4% 55.5% 19.8% -38.6% 197.0% -17.5% 41.6% 15.2%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 67.50
128.40
173.80
272.28
586.00
872.00
1,172.88
1,324.80
1,487.97
1,618.69
1,890.92
growth rate 90.2% 35.4% 56.7% 115.2% 48.8% 34.5% 13.0% 12.3% 8.8% 16.8%
Op.Income -170.40
15.90
57.80
124.98
261.00
372.00
450.02
557.92
640.10
613.84
715.93
growth rate 100.0% 263.5% 116.2% 108.8% 42.5% 21.0% 24.0% 14.7% -4.1% 16.6%
IBT 0.00
0.00
0.00
124.98
177.36
307.95
151.56
435.93
532.07
440.11
527.26
growth rate 41.9% 73.6% -50.8% 187.6% 22.1% -17.3% 19.8%
Net Income -184.30
-6.80
32.80
124.98
261.00
216.00
58.39
329.54
396.83
487.85
447.10
growth rate 0.0% 100.0% 281.1% 108.8% -17.2% -73.0% 464.4% 20.4% 22.9% -8.4%
EPS -7.19
-0.23
0.83
2.67
4.79
3.51
0.93
5.23
6.41
7.96
7.30
growth rate 0.0% 100.0% 221.7% 79.4% -26.7% -73.5% 462.4% 22.6% 24.2% -8.3%
Gross Profit 53.60
118.80
160.20
258.34
524.00
774.00
1,065.96
1,222.28
1,382.59
1,508.51
1,769.38
growth rate 121.6% 34.9% 61.3% 102.8% 47.7% 37.7% 14.7% 13.1% 9.1% 17.3%
R&D 70.00
36.60
25.60
14.12
20.48
41.63
85.18
133.45
160.40
196.04
222.62
growth rate -47.7% -30.1% -44.8% 45.0% 103.3% 104.6% 56.7% 20.2% 22.2% 13.6%

Quarterly Statements

Item Name Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Earnings BIT 149.21
87.81
196.10
188.78
185.46
growth rate -41.2% 123.3% -3.7% -1.8%
Balance Sheet Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Acct.Receivable 224.13
281.42
278.44
279.44
263.84
growth rate 25.6% -1.1% 0.4% -5.6%
Acct.Payable 24.37
46.93
31.38
37.37
40.60
growth rate 92.6% -33.1% 19.1% 8.6%
Cur.Assets 968.28
1,126.32
1,306.93
1,464.39
1,234.01
growth rate 16.3% 16.0% 12.1% -15.7%
Total Assets 5,123.67
5,287.13
5,348.97
5,485.79
5,203.49
growth rate 3.2% 1.2% 2.6% -5.2%
Cash 386.04
453.17
485.08
499.02
309.62
growth rate 17.4% 7.0% 2.9% -38.0%
Inventory 43.25
46.38
46.16
43.44
52.96
growth rate 7.3% -0.5% -5.9% 21.9%
Cur.Liabilities 293.95
375.62
347.95
341.29
345.49
growth rate 27.8% -7.4% -1.9% 1.2%
Liabilities 2,410.58
2,500.56
2,479.22
2,458.47
2,446.07
growth rate 3.7% -0.9% -0.8% -0.5%
LT Debt 1,540.43
1,537.04
1,558.31
1,560.58
1,563.03
growth rate -0.2% 1.4% 0.2% 0.2%
Equity 2,713.10
2,786.57
2,869.75
3,027.32
2,757.42
growth rate 2.7% 3.0% 5.5% -8.9%
Common Shares 0.01
0.01
0.01
0.01
0.01
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Capital Expenditures 8.88
7.15
4.13
3.94
5.15
growth rate -19.5% -42.2% -4.7% 30.7%
Cash Dividends
growth rate
Cash From OA 204.56
162.36
191.62
220.58
224.35
growth rate -20.6% 18.0% 15.1% 1.7%
Sale Purchase of Stock 9.03
10.59
growth rate 17.2%
FCF 195.68
155.21
187.49
216.64
219.20
growth rate -20.7% 20.8% 15.5% 1.2%
Income Statement Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Sales 436.40
444.61
500.48
469.37
476.46
growth rate 1.9% 12.6% -6.2% 1.5%
Op.Income 149.21
87.81
196.10
188.78
185.46
growth rate -41.2% 123.3% -3.7% -1.8%
IBT 118.55
65.14
128.85
168.66
164.61
growth rate -45.1% 97.8% 30.9% -2.4%
Net Income 232.21
45.99
92.32
149.32
159.47
growth rate -80.2% 100.7% 61.7% 6.8%
EPS
growth rate
Gross Profit 411.15
410.69
465.77
442.80
450.12
growth rate -0.1% 13.4% -4.9% 1.7%
R&D 65.00
62.67
56.13
51.16
52.66
growth rate -3.6% -10.4% -8.9% 2.9%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

A (89.38)

YOY Growth Grade:

B (72.17)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 17.59 17.59 7.52
EPS / Growth 15.1% 7.30 16.5%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 41.6%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 15.1% 24.4% 24.4%
Future PE 7.52 14.23 24.64
Future EPS 29.79 64.79 64.79
Value Price
MOS %
55.41
-56.9%
227.98
77.5%
394.60
207.2%
MOS Price 27.70 113.99 197.30
IRT 8.49 6.82 6.82

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.